Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Study Identifier
M02-537
CT.gov Identifier
NCT00195689
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Psoriatic Arthritis (PsA)
    • Study Drug
  • Human anti-TNF monoclonal antibody/adalimumab
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subject completed study M02-518 or M02-570
    Exclusion Criteria:
    - Subject prematurely discontinued study M02-518 or M02-570 - Female subject who is pregnant or breast-feeding or considering becoming pregnant - Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

    Protocol Summary

    The purpose of the study is to assess the long-term safety and clinical efficacy of

    adalimumab in treatment of moderate to severely active psoriatic arthritis

    Study Locations

    Location
    Status
    Location
    Global Medical Information-Abbott Laboratories
    Abbott Park, Illinois, United States, 60064
    Status
    Not applicable